Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

JANX - Janux Therapeutics, Inc.

IEX Last Trade
55.145
0.075   0.136%

Share volume: 12,908
Last Updated: Thu 26 Dec 2024 08:29:25 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$55.07
0.08
0.14%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 3%
Liquidity 75%
Performance 1%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.07%
1 Month
16.96%
3 Months
20.42%
6 Months
41.06%
1 Year
437.74%
2 Year
378.60%
Key data
Stock price
$55.14
P/E Ratio 
-55.64
DAY RANGE
$54.94 - $55.84
EPS 
-$0.90
52 WEEK RANGE
$8.54 - $71.71
52 WEEK CHANGE
$379.83
MARKET CAP 
2.451 B
YIELD 
N/A
SHARES OUTSTANDING 
52.164 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
2.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$821,416
AVERAGE 30 VOLUME 
$1,632,289
Company detail
CEO: David Campbell
Region: US
Website: januxrx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Recent news